At the One Nucleus Building Life Science Adventures careers conference on 2 March 2022, Dr. John McCafferty, CSO and Founder, IONTAS Limited and CEO and Founder of Maxion Therapeutics, was announced winner of the Life Sciences Inspiration of the Year Award, sponsored and presented by Johnson & Johnson Innovation. This award recognises an ambassador for the Life Sciences, someone who has shown great leadership in building teams and who is an inspiration to others and John has certainly gone above and beyond in achieving this.
After completing a PhD in his hometown, Glasgow, and post-doc in…
Cambridge and London, UK, 29th March 2022: Mursla, a novel multi-omics exosome characterisation company, is pleased to announce that it has secured mentorship support from Roche Diagnostics Ltd for a new liquid biopsy prospective pilot study for liver cancer surveillance through MedCity’s Collaborate to Innovate: London Diagnostics programme. Liver cancer is the third most common cause of premature cancer death worldwide and its incidence has increased significantly over other forms of cancer in the last three decades.
Mursla’s aim is to develop a blood test that can detect early…
tranScrip, the fast-growing contract drug development organisation which supports the development and lifecycle of medicines, has acquired Dublin-based Real Regulatory, a highly respected business specialising in European regulatory affairs, quality systems and compliance for medical products.
The strategic acquisition significantly expands tranScrip’s regulatory affairs capabilities, strengthening its ability to provide comprehensive support to its customers. The deal is the first acquisition made by tranScrip since it secured the backing of private equity investor Palatine in 2021 via its…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS
Further strengthens the Company’s extensive patent portfolio protecting its proprietary Arestat™ technology and diabetes product portfolio
Cambridge, UK, 23 March 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the United States Patent and Trademark Office has granted a patent (US11278624) protecting novel formulations of the Group’s proprietary insulin products, AT247…
BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be presenting initial results from two of its hepatocyte research projects at the 2022 Society of Toxicology Annual Meeting and ToxExpo. The conference will be held from March 27-31 both virtually and in person in San Diego, CA.
“We’re excited to be back, in-person, meeting with the research community at SOT,” said Dr. Christopher Black, BioIVT Senior Vice President ADME-Tox. “During the past two years, our customers have shown remarkable skill in adapting to the…
Nottingham-based contract research organisation (CRO) Cellomatics Biosciences has appointed Anand Krishna as senior director to oversee customer engagement and strategy and support its continued growth plans.
Anand brings over 25 years of executive leadership and field sales management experience in companies ranging from VC-funded dotcom start-ups, to managing sales across portfolios in tier 1 technology systems and operations integrators. His career has seen him lead and work with teams across the US, UK, Europe, India, and the Far East.
He now focuses on working with entrepreneurs across…
SAN DIEGO, March 16, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) has invested in seven new genomics companies to join the fourth global funding cycle of Illumina Accelerator San Francisco Bay Area and Cambridge, UK. The global company creation engine is focused on partnering with entrepreneurs to build breakthrough genomics startups and its next global funding cycle application deadline is April 1, 2022.
Illumina Accelerator is accepting applications this month for its next global cohort of genomics startups, the deadline is April 1.
"A hands-on company creation engine and venture…
Monument Tx CSO to present novel biomarker predicting risk for developing POCD at AD/PD conference in Barcelona 15-20th March 2022
Manchester, UK, March 14, 2022: Monument Therapeutics, a stratified medicine company, today announced it will be presenting data to support their novel biomarker that can predict risk of an individual developing Post-Operative Cognitive Decline (POCD), at the AD/PD conference, 15-20th March 2022. Findings will be presented from the analysis of a large European dataset that included over 1000 patients that were cognitively and clinically assessed both before and…
Monument Tx CSO to present preclinical data for lipid reformulation of anti-inflammatory compound MT1980 at AD/PD conference in Barcelona 15-20th March 2022
Manchester, UK, March 14, 2022: Monument Therapeutics, a stratified medicine company, today announced it will be presenting their positive preclinical results for MT1980, a lipid-based reformulation of an on-market anti-inflammatory compound, at the AD/PD conference, 15-20th March 2022. Findings will be presented from preclinical pharmacokinetic and pharmacodynamic experiments that support the development of MT1980 for a range of major…
SCIENCE AND INNOVATION SECTORS IN CAMBRIDGE DRIVE GROWTH IN REGIONAL EMPLOYMENT DESPITE PANDEMIC TURBULENCE
Information technology, telecommunications, and the life sciences remain the largest and most dynamic of the knowledge intensive sectors
Cambridge, UK. 15th March 2022: New data covering the first full year of the pandemic (April 2020 to March 2021) shows the striking resilience of the Cambridge area to pandemic shocks. It reveals that the innovation clusters in the Cambridge city region – particularly Life Sciences and Information Technology – were the driving force of the local…